These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 26079252)

  • 1. Using circulating tumor cells to inform on prostate cancer biology and clinical utility.
    Li J; Gregory SG; Garcia-Blanco MA; Armstrong AJ
    Crit Rev Clin Lab Sci; 2015; 52(4):191-210. PubMed ID: 26079252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer.
    Bitting RL; Healy P; Halabi S; George DJ; Goodin M; Armstrong AJ
    Urol Oncol; 2015 Mar; 33(3):110.e1-9. PubMed ID: 25595577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.
    Strati A; Zavridou M; Bournakis E; Mastoraki S; Lianidou E
    Analyst; 2019 Nov; 144(22):6671-6680. PubMed ID: 31596277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer.
    Groen L; Kloots I; Englert D; Seto K; Estafanos L; Smith P; Verhaegh GW; Mehra N; Schalken JA
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Utility of Circulating Tumor Cells in Advanced Prostate Cancer.
    Zhang T; Armstrong AJ
    Curr Oncol Rep; 2016 Jan; 18(1):3. PubMed ID: 26700506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of circulating tumor cells in guiding treatment decisions for patients with metastatic castration-resistant prostate cancer.
    Onstenk W; de Klaver W; de Wit R; Lolkema M; Foekens J; Sleijfer S
    Cancer Treat Rev; 2016 May; 46():42-50. PubMed ID: 27107266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.
    Massard C; Oulhen M; Le Moulec S; Auger N; Foulon S; Abou-Lovergne A; Billiot F; Valent A; Marty V; Loriot Y; Fizazi K; Vielh P; Farace F
    Oncotarget; 2016 Aug; 7(34):55069-55082. PubMed ID: 27391263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Androgen Receptor Variant 7 (
    Hille C; Gorges TM; Riethdorf S; Mazel M; Steuber T; Amsberg GV; König F; Peine S; Alix-Panabières C; Pantel K
    Cells; 2019 Sep; 8(9):. PubMed ID: 31514447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating tumor cells as a predictive biomarker in patients with hormone-sensitive prostate cancer.
    Goodman OB; Symanowski JT; Loudyi A; Fink LM; Ward DC; Vogelzang NJ
    Clin Genitourin Cancer; 2011 Sep; 9(1):31-8. PubMed ID: 21705286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population.
    Heller G; Fizazi K; McCormack R; Molina A; MacLean D; Webb IJ; Saad F; de Bono JS; Scher HI
    Clin Cancer Res; 2017 Apr; 23(8):1967-1973. PubMed ID: 27678453
    [No Abstract]   [Full Text] [Related]  

  • 12. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.
    Goldkorn A; Ely B; Tangen CM; Tai YC; Xu T; Li H; Twardowski P; Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Vogelzang NJ; Thompson IM; Cote RJ; Quinn DI
    Int J Cancer; 2015 Apr; 136(8):1856-62. PubMed ID: 25219358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
    Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
    Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature.
    Singhal U; Wang Y; Henderson J; Niknafs YS; Qiao Y; Gursky A; Zaslavsky A; Chung JS; Smith DC; Karnes RJ; Chang SL; Feng FY; Palapattu GS; Taichman RS; Chinnaiyan AM; Tomlins SA; Morgan TM
    Mol Cancer Res; 2018 Apr; 16(4):643-654. PubMed ID: 29453313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients.
    Cho WJ; Oliveira DS; Najy AJ; Mainetti LE; Aoun HD; Cher ML; Heath E; Kim HR; Bonfil RD
    J Transl Med; 2016 Mar; 14():72. PubMed ID: 26975354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Biomarkers in metastatic castration-resistant prostate cancer].
    Miller K
    Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multigene model for predicting metastatic prostate cancer using circulating tumor cells by microfluidic magnetophoresis.
    Cho H; Chung JI; Kim J; Seo WI; Lee CH; Morgan TM; Byun SS; Chung JS; Han KH
    Cancer Sci; 2021 Feb; 112(2):859-870. PubMed ID: 33232539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor Cells in Prostate Cancer: From Discovery to Clinical Utility.
    Pantel K; Hille C; Scher HI
    Clin Chem; 2019 Jan; 65(1):87-99. PubMed ID: 30602476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Shen T; Halabi S; Kemeny G; Bitting RL; Kartcheske P; Embree E; Morris K; Winters C; Jaffe T; Fleming M; George DJ
    Clin Genitourin Cancer; 2013 Dec; 11(4):397-406. PubMed ID: 23830964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and Application of Liquid Biopsies in Metastatic Prostate Cancer.
    Morrison GJ; Goldkorn A
    Curr Oncol Rep; 2018 Mar; 20(4):35. PubMed ID: 29572775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.